The reiteration of an Overweight rating and the maintenance of a $135 price target by a reputable analyst firm like Cantor Fitzgerald could instill confidence among investors about Merck & Co's future prospects. This positive endorsement is likely to influence investor sentiment positively in the short term, potentially leading to an uptick in MRK's stock price.